News

Ambrx ARX788 may hold the potential for a broader patient population than the currently available Her2 targeting therapies. The multicenter study will be conducted at several sites within

The move is part of a new initiative to counter the disease. Researchers expect to deliver results in 18 months, working with a smallpox virus derivative that may

The drug, however, did not show enough benefit in related inattention and mood complications. Pegvaliase is being tested against a placebo in patients of Phenylketonuria (PKU) or phenylalanine

The decision follows the submission of new evidence on the drug’s benefits. Last December, the agency turned down Zytiga for patients whose chemotherapy is not yet indicated after

A study by the University of Cincinnati found the fruit could improve thinking skills and the memory of people who had mild cognitive problems. 47 adults aged 68

The drug is a ready-to-use version of The Medicines Co’s blood clot preventer Angiomax, which should also to be taken with aspirin. It is intended for use as

These data showed the BRIDGE study met the primary endpoint, demonstrating a statistically significant increase in bone mineral density (BMD) at the lumbar spine (as assessed by dual

Under the new arrangement, Helsinn Therapeutics Inc., the U.S. affiliate of Helsinn, will obtain exclusive rights to promote and sell AKYNZEO (netupitant/palonosetron), its oral fixed dose combination product

"Changes at InVivo Therapeutics after I left the company in August of 2013 have permanently limited wide market adoption of my first generation of NeuroScaffolds. PixarBio’s Novel NR-SCI